In the wake of InSymbiosis’ website re-launch, we are proud to headline our Strategic Investment Vehicle. We have been working quietly in the background on this over the last 18 months but we thought is was about time we brought you up to speed on what we are doing.

InSynchrony Ventures Inc. was founded by Dean Wenham (also founder of InSymbiosis) and some like-minded collaborators to form an investment arm that largely focuses on investing in earlier staged companies with assets in the preclinical to early clinical phases. By offering our skills, guidance and capital, we facilitate our partners to advance their programs to key inflection points where larger deals can be achieved.

To embark on this journey, we have invested in the following companies:

  • Genoa Pharmaceuticals is based in San Diego, California and are developing improved therapies for the treatment of Ideopathic Pulmonary Fibrosis
  • MHB Labs is based in Boston and are developing superior treatment for hypogonadism (low testosterone). They’ve developed AndroSpheres, the first extended release form of human chorionic gonadotropin
  • Vaxdyn is a Spanish based biotechnology company focused on the development of preventative vaccines against difficult to control bacteria such as Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and pathogenic E. coli.
  • Cetya Therapeutics is based in Colorado and is developing next generation histone deacetylase inhibitors (HDACi) for oncology.


Follow us to see who will be our future allies!

The InSymbiosis Team